相关实验视频
Updated: Jul 3, 2026

10:20
In vitro Measurements of Tracheal Constriction Using Mice
Published on: June 25, 2012
通过减少Pde3b,ESrrg抑制可以防止PM2.5诱导的喘恶化
Zhihua Zhang1,2, Tao Cai3, Xin Zhang4
1Hebei Chest Hospital, Department of Science and Education, Shijiazhuang, Hebei, China.
American journal of respiratory cell and molecular biology
|March 28, 2025
概括
抑制雌激素相关受体玛 (Esrrg) 降低了喘模型中PM2.5暴露引起的呼吸道炎症和细胞损伤. Esrrg 向基化酶3B (Pde3b),使PM2.5引起的喘恶化.
科学领域:
- 环境健康 环境健康
- 分子生物学分子生物学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 颗粒物物质2.5 (PM2.5) 暴露会加剧喘.
- 雌激素相关受体gamma (Esrrg) 是一个参与代谢疾病的核受体.
- 对于PM2.5诱导的喘恶化中Esrrg的作用尚不清楚.
研究的目的:
- 调查Esrrg在PM2.5引发的喘恶化的作用.
- 在PM2.5加重喘的小鼠模型中探索Esrrg抑制的治疗潜力.
主要方法:
- 通过将卵素 (OVA) 敏感的小鼠暴露在PM2.5.5中,建立了一种喘恶化的小鼠模型.
- 利用mRNA测序来识别差异表达的基因,包括Esrrg.
- 采用腺相关病毒 (AAV) 介导的shRNA (shEsrrg) 和药理抑制 (GSK5182) 来抑制Esrrg在体内和体外.
- 评估了呼吸道炎症,MTEC损伤和Pde3b表达.
- 通过双 luciferase 记者和 ChIP-PCR 试验证实了 Esrrg 与 Pde3b 促进体的结合.
主要成果:
- 在OVA诱导的喘中,Esrrg显著上调,并且在PM2.5暴露时进一步增加.
- 在PM2.5加重的喘小鼠中,Esrrg抑制 (shEsrrg或GSK5182) 改善了呼吸道炎症和MTEC损伤.
- Esrrg 抑制降低了二酶3B (Pde3b) 的表达.
- Esrrg 直接与 Pde3b 促进体结合.
结论:
- 在PM2.5加重喘模型中,ESrrg抑制减轻了呼吸道炎症.
- 通过向Pde3b促进体,ESrrg抑制可以防止PM2.5诱导的MTEC损伤.
- Esrrg 是PM2.5加重喘的潜在治疗标.
相关概念视频
Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

